Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial) by Pieter C van der Sluis et al.
TRIALS
van der Sluis et al. Trials 2012, 13:230
http://www.trialsjournal.com/content/13/1/230STUDY PROTOCOL Open AccessRobot-assisted minimally invasive
thoraco-laparoscopic esophagectomy versus
open transthoracic esophagectomy for resectable
esophageal cancer, a randomized controlled
trial (ROBOT trial)
Pieter C van der Sluis1*, Jelle P Ruurda1, Sylvia van der Horst1, Roy JJ Verhage1, Marc GH Besselink1,
Margriet JD Prins1, Leonie Haverkamp1, Carlo Schippers1, Inne HM Borel Rinkes1, Hans CA Joore2,
Fiebo JW ten Kate3, Hendrik Koffijberg4, Christiaan C Kroese5, Maarten S van Leeuwen6, Martijn PJK Lolkema7,
Onne Reerink8, Marguerite EI Schipper3, Elles Steenhagen4, Frank P Vleggaar9, Emile E Voest7,
Peter D Siersema9 and Richard van Hillegersberg1*Abstract
Background: For esophageal cancer patients, radical esophagolymphadenectomy is the cornerstone of
multimodality treatment with curative intent. Transthoracic esophagectomy is the preferred surgical approach
worldwide allowing for en-bloc resection of the tumor with the surrounding lymph nodes. However, the
percentage of cardiopulmonary complications associated with the transthoracic approach is high (50 to 70%).
Recent studies have shown that robot-assisted minimally invasive thoraco-laparoscopic esophagectomy (RATE) is at
least equivalent to the open transthoracic approach for esophageal cancer in terms of short-term oncological
outcomes. RATE was accompanied with reduced blood loss, shorter ICU stay and improved lymph node retrieval
compared with open esophagectomy, and the pulmonary complication rate, hospital stay and perioperative
mortality were comparable. The objective is to evaluate the efficacy, risks, quality of life and cost-effectiveness of
RATE as an alternative to open transthoracic esophagectomy for treatment of esophageal cancer.
Methods/design: This is an investigator-initiated and investigator-driven monocenter randomized controlled
parallel-group, superiority trial. All adult patients (age ≥18 and ≤80 years) with histologically proven, surgically
resectable (cT1-4a, N0-3, M0) esophageal carcinoma of the intrathoracic esophagus and with European Clinical
Oncology Group performance status 0, 1 or 2 will be assessed for eligibility and included after obtaining informed
consent. Patients (n = 112) with resectable esophageal cancer are randomized in the outpatient department to
either RATE (n = 56) or open three-stage transthoracic esophageal resection (n = 56). The primary outcome of this
study is the percentage of overall complications (grade 2 and higher) as stated by the modified Clavien–Dindo
classification of surgical complications.
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Discussion: This is the first randomized controlled trial designed to compare RATE with open transthoracic
esophagectomy as surgical treatment for resectable esophageal cancer. If our hypothesis is proven correct, RATE
will result in a lower percentage of postoperative complications, lower blood loss, and shorter hospital stay, but
with at least similar oncologic outcomes and better postoperative quality of life compared with open transthoracic
esophagectomy. The study started in January 2012. Follow-up will be 5 years. Short-term results will be analyzed
and published after discharge of the last randomized patient.
Trial registration: Dutch trial register: NTR3291 ClinicalTrial.gov: NCT01544790Background
In 2008 an estimated 482,300 people were diagnosed
with esophageal cancer, and 406,800 patients died of the
disease worldwide [1]. Radical esophagolymphadenect-
omy is the cornerstone of the multimodality treatment
with curative intent [2-5].
Transthoracic esophagectomy is the preferred surgi-
cal approach worldwide allowing for en-bloc resection
of the tumor with the surrounding para-tracheal,
subcarinal and para-esophageal lymph nodes [6,7].
However, the percentage of cardiopulmonary compli-
cations associated with the transthoracic approach is
high (50 to 70%) [6].
Minimally invasive esophagectomy was designed to
reduce surgical trauma, resulting in lower morbidity
and mortality rates. With regard to minimally invasive
esophagectomy, review of the literature shows a sub-
stantial decrease in blood loss, postoperative compli-
cations and days of hospital stay, with comparable
oncologic results [8-12].
In 2003 the robot-assisted thoraco-laparoscopic
approach was developed at the University Medical
Center Utrecht (UMCU), the Netherlands [13]. Robot-
assisted thoraco-laparoscopic esophagectomy facilitates
complex minimally invasive procedures with an enlarged,
three-dimensional field of view. The articulated instru-
ments allow dissection with seven degrees of freedom
[13,14].
Until now there have been no prospective randomized
controlled trials comparing robot-assisted minimally
invasive esophagectomy with conventional open trans-
thoracic esophagectomy. We present the protocol of the
first randomized controlled trial comparing these two
surgical approaches.
Aim of the study
This is a randomized controlled parallel-group, super-
iority trial of robot-assisted thoraco-laparoscopic eso-
phagectomy versus open three-stage transthoracic
esophagectomy in patients with resectable intrathor-
acic esophageal cancer.Methods
Objectives
Patients with resectable esophageal cancer are ran-
domized at the outpatient department to either robot-
assisted thoraco-laparoscopic esophagectomy or open
three-stage transthoracic esophageal resection. The
objective is to evaluate the efficacy, risks and cost-
effectiveness of robot-assisted thoraco-laparoscopic
esophagectomy as an alternative to open transthoracic
esophagectomy as treatment for esophageal cancer.
We hypothesize that robot-assisted minimally invasive
thoraco-laparoscopic esophagectomy leads to a lower
postoperative complication rate, less blood loss and a
shorter hospital stay, with similar oncologic outcomes
and better postoperative quality of life, compared with
the open transthoracic esophagectomy (current refer-
ence standard of care).
Study design
This is an investigator-initiated and investigator-driven
randomized controlled parallel-group, superiority trial
comparing robot-assisted thoraco-laparoscopic esopha-
gectomy with traditional open three-stage transthoracic
esophageal resection.
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki [15] and Good Clinical
Practice Guidelines [16]. The independent ethics commit-
tee of the UMCU has approved the study. Written
informed consent will be obtained from all participating
patients. Clinical trial monitoring will be conducted by an
independent data monitor (Julius Clinical Research, Zeist,
the Netherlands).
Study population
All adult patients (age ≥18 and ≤80 years) with histologi-
cally proven, surgically resectable (cT1-4a, N0-3, M0)
squamous cell carcinoma, adenocarcinoma or undifferen-
tiated esophageal carcinoma of the intrathoracic esopha-
gus will be assessed for eligibility. Patients should have a
performance status 0, 1 or 2 according to the European
Clinical Oncology Group.
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Inclusion criteria
 Histologically proven squamous cell carcinoma,
adenocarcinoma or undifferentiated carcinoma of
the intrathoracic esophagus (including Siewert I
and II).
 Surgically resectable (T1-4a, N0-3, M0).
 Age ≥18 and ≤80 years.
 European Clinical Oncology Group performance
status 0,1 or 2.
 Written informed consent.
Exclusion criteria
 Carcinoma of the cervical esophagus.
 Carcinoma of the gastro-esophageal junction with
the main part of the tumor in the gastric cardia
(Siewert type III).
 Prior thoracic surgery at the right hemithorax or
thoracic trauma.Study protocol
Patients are informed about the trial by one of our sur-
geons (RvH or JPR) at the outpatient department. After
receiving the information, all patients have 1 week to
consider their consent. After 1 week, patients are
contacted by the coordinating researcher (PCvdS) to
make an appointment to obtain and register informed
consent.
After obtaining informed consent, randomization is
done by computer-generated random numbers. Con-
cealment of allocation is maintained by using sealed
opaque envelopes. There is no blinding for the pa-
tient, surgeon and coordinating researcher because
this is difficult in daily practice. However, the
independent data monitoring safety committee is
blinded to the allocated intervention. Within 1 week,
patients will be informed about the allocated treat-
ment. This study is completed funded by the Depart-
ment of Surgery, UMCU. Multiple esophageal cancer
biopsies for pathological analysis will be obtained
through esophagogastroscopy, of which four biopsies
will be snap frozen and stored for translational re-
search. The physical status of the patient is assessed
and preoperative testing is guided by institutional
guidelines [17].
Neoadjuvant (radio)chemotherapy will be administered
according to the current policy in the Netherlands and the
UMCU [17]. Two additional blood samples will be
obtained for translational research (proteomics) at the fol-
lowing times: before start of neoadjuvant treatment, theday of operation, after adjuvant treatment and with suspi-
cion of recurrent disease.
After finishing preoperative neoadjuvant treatment,
patients will be evaluated with a second computed tom-
ography scan for metastases and resectability. When the
tumor is considered to be resectable, patients will
undergo the randomized intervention – either robot-
assisted thoraco-laparoscopic esophagectomy or open
three-stage transthoracic esophagectomy depending on
randomization.
All resection specimens will be preserved and stored
(biobank, tissue-microarray) for translational research.
The study started on 1 January 2012. Inclusion will
take approximately 3 years. Follow-up for each patient
will be 5 years. The total duration of the study will be 8
years.Surgery
All procedures (robot-assisted thoraco-laparoscopic
esophagectomy or open transthoracic esophagectomy)
will be carried out by the same experienced surgeons in
the UMCU (JPR and RvH). All patients will receive an
epidural catheter to provide adequate postoperative
analgesia. Patients will be intubated with a left-sided
double-lumen tube to enable selective desufflation of
the right lung during the thoracic phase in both
procedures.
Prophylactic antibiotics cefazolin (2,000 mg) and
metronidazole (500 mg) will be administered 30 min-
utes prior to incision [14]. An intravenous injection of
10 mg/kg methylprednisolone will be administered 30
minutes prior to incision to minimize postoperative
pulmonary complications [18]. During single-lung ven-
tilation, a pressure-controlled ventilation strategy will
be used with a maximum pressure of 20 cm H2O [19].Open three-stage transthoracic esophagectomy
The patient is placed in a left lateral decubitus position
and the procedure commences with a right posterolat-
eral thoracotomy. After incision and desufflation of the
right lung, the pulmonary ligament is incised followed
by identification of the azygos vein. The azygos vein is
clipped and ligated at the level of the azygos arch. The
thoracic duct is identified, clipped and ligated. The
esophagus is resected en bloc with the surrounding
mediastinal lymph nodes. The resected specimen will
contain right-sided paratracheal (lymph node station
2R), tracheobronchial (lymph node station 4), aorto-
pulmonary window (station 5), carinal (station 7) and
peri-esophageal (station 8) lymph nodes [20].
Chest tubes are placed and the thoracotomy wound is
closed using intracutaneous closure with absorbable
sutures.
Figure 1 Trocar arrangement during the robot-assisted
thoracoscopic phase. (a) Trocar arrangement during robot-assisted
thoracoscopic phase. La, left robotic arm (fourth intercostal space);
a, assistant thoracoscopic working port (fifth and seventh intercostal
space); ca, robotic camera arm (sixth intercostal space); ra, right
robotic arm (eighth intercostal space) [14]. (b) Trocar arrangement
during the laparoscopic abdominal phase. The camera was inserted
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abdominal phase via supra-umbilical laparotomy. The
stomach is mobilized with special care for the gastroepi-
ploic and short gastric vessels. The left gastric artery is
identified, clipped and ligated. Lymph node dissection is
performed around the celiac trunk and the lesserthrough the 10 mm para-umbilical trocar port and two 5 mm
trocars were used as laparoscopic working ports. The liver retractor
was inserted through the 12 mm right para-rectal trocar port. The
harmonic scalpel was inserted through the 12 mm paraumbilical
port [14].omentum. A linear stapler (GIATM 80, 3.8 mm; Covi-
dien, Mansfield, MA, USA) is used to create a gastric
conduit 4 cm wide, which is routinely oversewn [21].
The gastric conduit is pulled up through the mediasti-
num along the original anatomic tract of the esophagus
with the aid of a plastic tube (laparoscopic camera bag).
A cervical handsewn end-to-side anastomosis is created
between the gastric tube and the cervical esophagus
using a 3/0 polydioxanone single-layer running suture.
A feeding jejunostomy is placed in the second loop after
the ligament of Treitz for postoperative feeding. The ab-
domen is closed in layers with PDS loop for the fascia
and skin intracutaneously with monocryl. Patients are
transferred to the ICU after the surgical procedure.Robot-assisted minimally invasive thoraco-laparoscopic
esophagectomy
Robot-assisted minimally invasive thoraco-laparoscopic
esophagectomy was described previously [14]. For the
thoracic phase, the patient is positioned in the left
lateral decubitus position, tilted 45° towards the prone
position. The robotic system (daVinci Si; Intuitive Surgical
Inc., Sunnyvale, CA, USA) is brought into the field at the
dorsocranial side of the patient. Three ports are placed for
the robotic system as well as two thoracoscopic ports for
the assisting surgeon (Figure 1a). After incision and instal-
lation of the operation robot and selective desufflation of
the right lung, the pulmonary ligament is divided.
Hereafter, the parietal pleura is dissected at the anter-
ior side of the esophagus from the diaphragm up to the
azygos arch. The azygos vein is ligated with Hem-o-lok
(Teleflex Medical, Weck Drive, NC, USA) and divided
[22]. Dissection of the parietal pleura is continued
above the azygos arch to establish dissection of the right
paratracheal lymph nodes. At the posterior side of the
esophagus, the parietal pleura is dissected cranially to
caudally along the azygos vein, including the thoracic
duct. The thoracic duct is clipped with a 10 mm en-
doscopic clipping device (Endoclip™ II; Covidien) to
prevent chylous leakage. To facilitate esophageal
mobilization a penrose drain is placed around the
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mobilization. The esophagus is resected en bloc with the
surrounding mediastinal lymph nodes. The resection
specimen will contain the same lymph nodes as
described for the open procedure.
For the abdominal phase, the patient is placed in a
supine position. Figure 1b shows the position of the
laparoscopic trocars. The lesser omentum is opened
and transected closely to the liver, until the left crus
of the diaphragm is reached. Hereafter, the greater
gastric curvature is dissected using a harmonic ace.
An abdominal lymphadenectomy is performed includ-
ing lymph nodes surrounding the celiac trunk, along
the left gastric and splenic artery and the lesser
omental lymph nodes. The left gastric artery and vein
are ligated with Hem-o-lok (Teleflex Medical) and
transected at their origin.
Through a left-sided vertical incision along the
sternocleidomastoid muscle, the cervical phase of eso-
phagectomy is initiated to facilitate mobilization of
the cervical esophagus. No formal cervical lymph
node dissection is carried out, but macroscopically
suspected cervical lymph nodes are dissected. The
cervical esophagus is transected and a cord is
attached to the specimen. The dissected esophagus en
bloc with the surrounding lymph nodes are pulled
down through the mediastinum under laparoscopic
view.
Hereafter, the left para-umbilical trocar port is
widened to a 5 to 7 cm transverse transabdominal in-
cision. The resection specimen is removed through
this incision with a wound drape (3M) to create the
gastric conduit extracorporally. A linear stapler
(GIATM 80, 3.8 mm; Covidien) is used to create a
gastric conduit 4 cm wide, which is routinely over-
sewn [21]. The gastric conduit is pulled up through
the mediastinum along the original anatomic tract of
the esophagus with the aid of a plastic tube (laparo-
scopic camera bag). A cervical handsewn end-to-side
anastomosis is created between the gastric tube and
the cervical esophagus using a 3/0 polydioxanone
single-layer running suture. A feeding jejunostomy is
placed in the second loop after the ligament of Treitz
for postoperative feeding. The abdomen is closed in
layers with PDS loop for the fascia and skin intracu-
taneously with monocryl. Patients are transferred to
the ICU after the surgical procedure.Outcome measurements
In terms of short-term oncological outcomes, we expect
the robot-assisted esophagectomy to be equivalent to
the open approach for survival but accompanied by
fewer complications [9-12]. The primary outcome ofthis study is therefore the percentage of overall compli-
cations (grade 2 and higher) as stated by the modified
Clavien–Dindo classification (MCDC) of surgical com-
plications [23].
Secondary biochemical outcomes include individual com-
ponents of the primary endpoint (major complications;
MCDC grades II to IV), including myocardial infarction,
anastomotic leakage (clinical or radiologic diagnosis),
anastomotic stenosis, chylothorax (chylous leakage,
presence of chylous in chest tubes or indication to start
low fat (2%)-containing tube feeding; VivonexW T.E.N.;
Nestlé, Lutry, Switzerland ), gastric tube necrosis
(proven by gastroscopy), pulmonary embolus, deep vein
thrombosis, vocal cord palsy or paralysis. Minor compli-
cations (MCDC grade I) will also be recorded. These in-
clude, for example, wound infections, pleural effusions
and delayed gastric emptying.
Length of ICU–medium care unit stay (days), length of
hospital stay (days), in hospital mortality and mortality
within 30 and 60 days will be reported. For all patients,
the cause of death will be noted. If applicable, the results
of the autopsy report will be noted. Two-year, 3-year and
5-year disease-free survival and overall survival will be
reported.
The operation time is defined as time from incision until
closure (minutes) for both the thoracic phase and the
abdominal phase of the procedure. For the robotic
procedure, the set-up time will be recorded separately.
Unexpected events and complications occurring during
the operation will be recorded (for example, hemorrhage
requiring transfusion, perforation of other organs) as well
as blood loss during operation (milliliters per phase). In
the case of conversion to thoracotomy or laparotomy, the
reason for conversion has to be explained (absolute
numbers/percentage).
The resected specimen will be marked by the surgical
team for the position of lymph node dissection. Evaluation
will be performed by an experienced pathologist using
standard protocols. Stage grouping will take place accord-
ing to the Union Internationale Contre le Cancer protocol
using the Tumor, Node, Metastasis-7 classification [24].
Exact localization of the lymph nodes is an essential part
of the pathologic examination [20]. The pathology report
contains the following parameters: site of tumor, type and
gradation, extension in the esophageal wall, margins of the
resection, extent of resection (R0 (oncological radical
resection), R1 or R2) [25], lymph node status with the
number of lymph nodes, tumor regression grade (accord-
ing to Mandard and colleagues) [26], vaso-invasion and
perineural growth. Quality control of pathology will be
provided by a specialized gastrointestinal pathologist
(FJWtK).
The type and dose of used analgesics will be noted
during the hospital admission period. A visual analogue
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preoperatively, the first 10 days after surgery and a fixed
period during follow-up (6 weeks, 6 months and yearly
postoperatively up to 5 years).
The quality-of-life questionnaires Short Form-36,
EORTC Quality-of-life Questionnaire Core 30 (Dutch),
EORTC OES18 (Dutch) and EQ-5D (Appendices 1 and
2) will be required at the following times: preoperatively
<5 days, and 6 weeks, 6 months and yearly up to 5 years
postoperatively.
The approach for the cost analysis is comparing ac-
tual direct medical costs incurred with both strategies
up until 5 years after the operation. Costs estimates
will be based on the recorded volumes and unit costs
associated with both procedures. This includes the
costs of operation rooms, costs of hospital and ICUFigure 2 Flowchart for the ROBOT trial.stays, and costs associated with complications and
reoperations.
Sample size calculation
Hypothesis: Compared with an open transthoracic eso-
phagectomy, robot-assisted thoraco-laparoscopic eso-
phagectomy will result in a lower percentage of overall
complications (MCDC grade 2 and higher). In a
prospective analysis of our own series, MCDC grade 2
to 5 complications were observed in 69% of all patients
who underwent robot-assisted thoraco-laparoscopic
esophagectomy and in 91% of all patients who under-
went open transthoracic esophagectomy in our won
series in the UMCU (2003 to 2010). We calculated that
102 patients (51 in each arm) with resectable esophageal
cancer would be required to detect this 22% reduction
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to 69% of patients) based on a two-sided significance
level (alpha) of 0.05 and a power of 0.80. An estimated
compensation of 10% for drop out is included in the
total number of patients, resulting in a total of 112
patients, 56 in each arm. Figure 2 visualizes the final
design.
Statistical analysis
All prospective data will be statistically analyzed using
SPSS statistical software (SPSS Inc. Chicago, Illinois,
USA. Data analysis will be performed in accordance with
the intention-to-treat principle; additional per-protocol
analysis will also be performed for tumor type, tumor
stage and type of neoadjuvant treatment.
To evaluate significance of differences between the
two groups, chi-squared and Fisher's exact tests will be
used as appropriate for categorical variables, and the
nonparametric Mann–Whitney U test for continuous
variables.
To evaluate differences in disease-free and overall sur-
vival, Kaplan–Meier survival curves will be computed.
Survival curves will be compared by log-rank test and
multivariable analysis will be accomplished by the Cox
regression model. The significance level will be set at 5%.
The approach for the cost analysis is comparing actual
direct medical costs incurred with both strategies up
until 5 years after the operation. Cost estimates will be
based on the recorded volumes and unit costs asso-
ciated with both procedures. This includes the costs of
operation rooms, costs of hospital and ICU stays, and
costs associated with complications and reoperations.
Pain scores will be analyzed using a linear mixed
model using repeated-measures analysis. The quality-
of-life questionnaires will be compared using covariance
analysis (preoperative scores as covariables). The cost-
effectiveness analysis will compare the mean costs and
effects for both strategies and result in an incremental
cost-effectiveness ratio. Uncertainty in the balance be-
tween costs and effects will be assessed with bootstrap-
ping. A time horizon of 5 years will be applied, and
costs and effects will be discounted according to Dutch
guidelines.
If the baseline characteristics differ after randomization –
that is, there is a lack of balance in the confounding
factors – this will be corrected using multivariate analysis
or using a net-benefit regression approach.
Interim analysis
There will be one interim analysis. The stopping rule
used for efficacy (that is, better outcome for the minim-
ally invasive method as the primary endpoint) is the
Peto approach, meaning P <0.001. The trial will not be
stopped for futility (that is, no difference) as the robot-assisted minimally-invasive approach is being used by a
growing numbers of centers worldwide and the out-
come of all endpoints of this first randomized trial on
this subject are relevant to healthcare professionals
involved with this procedure in those hospitals. As is
advised by the Dutch Central Committee on Research
involving Human Subjects (CCMO), there is no formal
stopping rule for harm.
After every 25 patients, individualized patient descrip-
tion charts including safety parameters will be presented
to the Data Safety Monitoring Committee (DSMC). The
DSMC will discuss these in a plenary or telephone con-
ference with the study coordinator and principal investi-
gator present. If the suspects are harmed (that is, worse
outcome for the minimally invasive method) the DSMC
will inform the trial research group. The trial research
group will discuss in a plenary session together with the
DSMC the potential harm per patient and will deter-
mine whether a relationship can be drawn between the
minimally-invasive procedure and the adverse events.
Consensus will be reached and the Medisch Ethische
Toetsingscommissie will be informed.
Discussion
To the best of our knowledge this is the first randomized
controlled trial designed to compare robot-assisted min-
imally invasive thoraco-laparoscopic esophagectomy with
open transthoracic esophagectomy as surgical treatment
for resectable esophageal cancer.
In the 2010 revised Dutch esophageal carcinoma guide-
lines, open transthoracic esophagectomy is considered the
first-choice procedure for patients with resectable
esophageal carcinoma [17]. However, open transthor-
acic esophagectomy is accompanied with significant
morbidity, predominantly through cardiopulmonary
complications [6].
To reduce surgical trauma and morbidity of the open
transthoracic esophagectomy, minimally invasive proce-
dures have been designed to overcome this problem.
However, conventional (thoraco)scopic surgery has
some important limitations, such as a two-dimensional
view, disturbed eye–hand coordination and limited
degrees of freedom, which might limit the surgeon in
performing an optimal radical esophageal and medias-
tinal lymph node dissection [27].
To overcome the limitations of conventional (thoraco)
scopic surgery, the robot-assisted minimally invasive
thoraco-laparoscopic esophagectomy was developed in
the UMCU in 2003 [14]. Despite these unchallengeable
technical advantages, evidence behind its superiority
over the conventional open transthoracic esophagectomy
is still lacking. From a systematic review, which included
nine articles (130 cases) related to robot-assisted esopha-
gectomy, it was concluded that robot-assisted
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terms of short-term oncological outcomes, robot-
assisted minimally invasive thoraco-laparoscopic esopha-
gectomy was at least equivalent to the open transthoracic
approach for esophageal cancer [9-12,28]. Robot-assisted
minimally invasive thoraco-laparoscopic esophagectomy
was accompanied with reduced blood loss, shorter ICU
stay and improved lymph node retrieval compared with
open esophagectomy, and the pulmonary complication
rate, hospital stay and perioperative mortality were
comparable [28]. Disadvantages of the robot-assisted
thoraco-laparoscopic esophagectomy were reported to
be a prolonged operative time and high costs consist-
ing of acquisition of an operation robot and dispos-
able tools [28].
The level of evidence for robot-assisted minimally in-
vasive thoraco-laparoscopic esophagectomy is subopti-
mal and based on case series or expert opinions only
(level 4 or 5) [28]. The systematic review strongly
emphasized the need for well-conducted randomized
controlled trials and long-term survival studies within
a framework of measured and comparable outcomes
to prove the superiority of robot-assisted minimally
invasive thoraco-laparoscopic esophagectomy over the
worldwide current standard open transthoracic eso-
phagectomy [28].
Two articles about conventional minimally invasive eso-
phagectomy were published recently [29,30]. Results from
both articles show that minimally invasive esophagectomy
in general is superior over open esophagectomy [29,30].
These results suggest that robot-assisted esophagectomy
might also be superior. One could argue that the real
question is whether robotic-assisted esophagectomy can
improve outcomes when compared with coventional
minimally invasive esophagectomy. However, with limited
evidence available for the superiority of robot-assisted eso-
phagectomy over open esophagectomy, it is too early to
compare robot-assisted esophagectomy with conventional
minimally invasive esophagectomy. Differences between
these groups will probably be small and therefore large
numbers of patients are needed to ensure enough statistical
power. Such a clinical trial can only be performed world-
wide in a multicenter fashion by surgeons who are experi-
enced in both techniques to avoid bias.
The UMCU has the largest experience worldwide with
robot-assisted thoraco-laparoscopic esophagectomy. Com-
bined with a completed learning curve, our centre is
considered the best place to compare robot-assisted eso-
phagectomy with open transthoracic esophagectomy. We
started this monocenter randomized controlled trial in
2012. This monocenter randomized controlled superiority
trial can provide further evidence supporting the robot-
assisted minimally invasive thoraco-laparoscopic esopha-
gectomy as treatment for resectable esophageal cancer.We anticipate that the inclusion for this study will take
3 years to complete. The study started in January 2012,
and follow-up will be 5 years. Short-term results will be
analyzed and published after discharge of the last rando-
mized patient.Conclusion
This is the first randomized controlled trial designed
to compare robot-assisted minimally invasive thoraco-
laparoscopic esophagectomy with open transthoracic
esophagectomy as surgical treatment for resectable
esophageal cancer.
If our hypothesis is proven correct, robot-assisted
minimally invasive thoraco-laparoscopic esophagectomy
will result in a lower percentage of postoperative com-
plications, lower blood loss and shorter hospital stay,
but with at least similar oncologic outcomes and better
postoperative quality of life compared with the open
transthoracic esophagectomy (current standard).Trial status
Recruitment of patients started in January 2012.
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